These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 37326121)

  • 21. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
    Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-based Screening for
    Chu JE; Johnson B; Kugathasan L; Morris VK; Raghav K; Swanson L; Lim HJ; Renouf DJ; Gill S; Wolber R; Karsan A; Kopetz S; Schaeffer DF; Loree JM
    Clin Cancer Res; 2020 Sep; 26(17):4599-4605. PubMed ID: 32571791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
    Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
    Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer.
    Lee CT; Chow NH; Chen YL; Ho CL; Yeh YM; Lin SC; Lin PC; Lin BW; Chu CA; Tsai HW; Lee JC
    Pathol Res Pract; 2021 Jan; 217():153288. PubMed ID: 33276219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinicopathological features and prognosis of sporadic mismatch repair deficient colorectal cancer].
    Wang H; Hong RP; Chen JC; Wang J; Zhang ZJ; Ren XY; Wu HW; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):702-708. PubMed ID: 38955702
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.
    Nunes L; Aasebø K; Mathot L; Ljungström V; Edqvist PH; Sundström M; Dragomir A; Pfeiffer P; Ameur A; Ponten F; Mezheyeuski A; Sorbye H; Sjöblom T; Glimelius B
    Acta Oncol; 2020 Apr; 59(4):417-426. PubMed ID: 31924107
    [No Abstract]   [Full Text] [Related]  

  • 31. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
    Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy: A European multicenter cohort study.
    Gkekas I; Jan N; Kaprio T; Beilmann-Lehtonen I; Fabian P; Tavelin B; Böckelman C; Edin S; Strigård K; Svoboda T; Hagström J; Barsova L; Jirasek T; Haglund C; Palmqvist R; Gunnarsson U
    J Surg Oncol; 2024 Jun; 129(7):1295-1304. PubMed ID: 38470492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF
    Grillo F; Paudice M; Pigozzi S; Dono M; Lastraioli S; Lugaresi M; Bozzano S; Tognoni C; Ali M; Sciallero S; Puccini A; Fassan M; Mastracci L
    Histopathology; 2024 Apr; 84(5):877-887. PubMed ID: 38173291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
    Rasola C; Laurent-Puig P; André T; Falcoz A; Lepage C; Aparicio T; Bouché O; Lievre A; Mineur L; Bennouna J; Louvet C; Bachet JB; Borg C; Vernerey D; Lonardi S; Taieb J
    Eur J Cancer; 2023 Nov; 194():113321. PubMed ID: 37797388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases.
    Flood MP; Jain A; Mitchell C; Hewitt C; Ramsay R; Michael M; Heriot AG; Tie J
    Eur J Surg Oncol; 2022 Oct; 48(10):2218-2225. PubMed ID: 35750576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.